Kinase Profiling Inhibitor Database

This is a searchable database of specificities of 55684 commonly used signal transduction inhibitors. These results have been provided by the International Centre for Kinase profiling within the MRC Protein Phosphorylation Unit at the University of Dundee.

We strongly recommend undertaking kinase profiling of any kinase inhibitor to be used in a biological experiment. It is essential to have a good feel for the specificity of the kinase inhibitor you are working with in order to be able to properly interpret your data.

If you have additional kinase inhibitors that you would like the International Centre for Kinase profiling team to profile for you please contact us here for further details.

If you have any feedback or suggestions on how to improve this resource we welcome your input. Pass on your ideas to us here.

Inhibitor Brutto MW Action Reference Screen Conc % Activity Remaining
GW5074 (Raf1 Kinase Inhibitor I)   C15H8Br2INO2 520.90 cRAF1 Lackey K. (2000) Bioorg. Med. Chem. Lett. 10 223

WO2010036813
 10.00 73
GW843682X (GSK-PLK1 Compound 2)   C22H18F3N3O4S 477.46 PLK1 Emmitte K.A. (2009) Bioorganic and Medicinal Chemistry Letters 19 1018-1021


 1.00 99
GW843682X (GSK-PLK1 Compound 2)   C22H18F3N3O4S 477.46 PLK1 Emmitte K.A. (2009) Bioorganic and Medicinal Chemistry Letters 19 1018-1021


 10.00 84
GW843682X (GSK-PLK1 Compound 2)   C22H18F3N3O4S 477.46 PLK1 Emmitte K.A. (2009) Bioorganic and Medicinal Chemistry Letters 19 1018-1021


 0.10 106
H-1152 (Rho Kinase Inhibitor)   C16H21N3O2S • 2HCl 392.30 ROCK Ikenoya M. (2002) J. Neurochem. 81 9
Sasaki Y. (2002) Pharmacol. Ther. 93 225
WO2010010702
 1.00 49
H-7, Dihydrochloride   C14H17N3O2S • 2HCl 364.30 serine/threonine kinases Ku W.C. (1997) Biochem. Biophys. Res. Commun. 241 730
Jarvis W.D. (1994) Cancer Res. 54 1707
WO1999041984
 10.00 67
H-8, Dihydrochloride   C12H15N3O2S • 2HCl 338.30 serine/threonine kinases Ido M. (1991) Br. J. Cancer 64 1103
Hagiwara M. (1987) Mol. Pharmacol. 31 523
WO1999041984
 10.00 63
H-89, Dihydrochloride   C20H20BrN3O2S • 2HCl 519.30 PKA Leemhuis J. (2002) J. Pharmacol. Exp. Ther. 300 1000
Davies S.P. (2000) Biochem. J. 351 95
WO2003080649
 10.00 87
H-89, Dihydrochloride   C20H20BrN3O2S • 2HCl 519.30 PKA Leemhuis J. (2002) J. Pharmacol. Exp. Ther. 300 1000
Davies S.P. (2000) Biochem. J. 351 95
WO2003080649
 1.00 93
HA-1077, Dihydrochloride (Fasudil)   C14H17N3O2S • 2HCl 364.30 PKA Watanabe K. (2007) Nature Biotechnology 25 681
Swärd K. (2000) J. Physiol. 522 33
WO1999041984
 10.00 52